LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study
| Autor: | Reinmuth, N., Özgüroğlu, M., Leighl, N.B., Galetta, D., Hacibekiroglu, I., Roubec, J., Sendur, M.A.N., Bria, E., Cicin, I., Grohé, C., Harputluoglu, H., Kilickap, S., Novello, S., Opalka, P., Riccardi, F., Ruseva, R.K., Lang, S., Hodari, M., Donner, N., de Marinis, F. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2023 20 Supplement |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|